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4.3 years (3 month–6 years). One patient died three months after the end of the treatment due to the tumor spread in CSF. We
observe local control at 1-year follow-up in 13 of the remaining patients (81%). Two patients relapsed in the cavernous sinus and
in Eustachian tube/middle ear respectively. Both patients were subsequently treated with reirradiation using IMRT achieving
a complete response that persists nowadays. Two patients (12%) died from lung metastasis without evidence of local relapse.
Side-effects: nasal dryness 60%, G1 and G2 xerostomia (33% and 7% of patients respectively), otitis media in 40%, esophageal
stenosis 7%. One of three patients with pericarotid tumor involvement developed massive hemorrhage due to the rupture of a
carotid aneurysm that required urgent vascular surgery. IMRT was associated with excellent local control and survival. Inclusion
of more patients and a longer follow-up are required to conﬁrm these results
http://dx.doi.org/10.1016/j.rpor.2013.03.268
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Background. We conducted a prospective study in patients with locoregionally advanced head and neck squamous cell can-
cer (LAHNC) to evaluate the feasibility and efﬁcacy of combining 3-drug taxane-containing induction chemotherapy (IC) with
radiation and concomitant single-agent cetuximab or cisplatin.
Methods. Three cycles of TPF induction chemotherapy with prophylactic G-CSF followed by deﬁnitive radiation and concurrent
cetuximab (400mg/m2 loading dose and 250mg/m2 per week during RT) or cisplatin (30mg/m2/w or 100mg/m2 120-h continuous
infusión of weeks 1 and 5). Radiotherapy was delivered with accelerated hyperfractionation concomitant boost (72Gy/42 fr/6w)
or standard fractionation (70Gy/35 fr/7w).
Results. There were 51 eligible and evaluable patients enrolled between May 1, 2007, and August 31, 2012. According to the AJCC 6
ed., 2010, 48 (94%) had stage IV disease and 3 (5.9%) stage III. Larynx 24 (45.5%) was the most common site followed by oropharynx
10 (19.6%), hypopharynx 10 (19.6%), oral cavity 3 (5.9%), nasopharynx 2 (3.9%) and paranasal sinus 1 (1.9%). Concurrent with
radiotherapy 42 patients (82.3%) received cetuximab and 9 patients (17.6%) cisplatin. The percentage of patients completing ICT
was 98.04%, radiation 100%, and cetuximab or cisplatin 98%. During TPF G 3 non-haematological toxicity occurred in 7 patients
(13.7%) and G4 in 2 (3.9%). Acute G 3–4 toxicity of concurrent treatment included dermatitis in 37 patients (36 G3, 1 G4) and
mucositis in 39 (38 G3, 1 G4). Forty-ﬁve percent of patients received enteral feeding. The overall response rate was 94.1%. Tumor
response (RECIST) at 12 weeks following completion treatment was 64.7% complete response and 29.4% partial response. The
2.5-year overall survival estimates were 58.1%, with 2.5-year progression-free survival estimates of 55.3% and 2-year local control
estimates of 81.3%.
Conclusions. Triple drug-based sequential therapy in patients with LAHNC is tolerable, with encouraging efﬁcacy.
http://dx.doi.org/10.1016/j.rpor.2013.03.269
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Purpose. Is described our experience in protocol for adaptive radiotherapy for head and neck tumors treated with Boost integrated
IMRT.
Material and method. IMRT in head and neck cancer provides an essential role in such diseases, and this technique provides a high
level of coverage with a low threshold dose distribution in critical organs (cord, brainstem, mandible, parotid glands), comparing
to 3D conventional technique. (a) Starting from 2011 we began conducting the protocol to assess replanning in IMRT: a new
CT-scan is performed at 4 weeks from starting treatment and is fussioned with the preplanning-CT as a dose of 45Gy; when
there nodal regression and inclusion of the parotids to the high dose region, and for that dose, weight loss is more apparent on
the anatomical structures of the head and neck. (b) 79 patients were treated between 2011 and 2012 with the diagnosis head
and neck cancer. We report our experience for replanning in IMRT treatment. (c) 14 of 79 patients (17%) were replaniﬁcated with
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following diagnosis: 2 of larynx, 3 oropharynx, 2 oral cavity, 2 unknown cervical metastasis, 2 nasopharynx, 1 hypopharynx, 1
paranasal sinus.
Results. The most of replanning was performed by weight loss secondary to mucositis, despite closed attention by the nursing
and nutritionist staff. In the graphical results are expressed lost weight and changes in the volume of primary PTV. Is made a
Pearson’s regression study and it is observed, despite the small number of patients, the decreased amount of the PTVs between
0 and 60 cm3, is independent of the amount of weight loss of the patient.
Conclusions. (a) IMRT maximizes tumor coverage and sparing of critical organs (OARs). Anatomical changes are more dramatic
than in conventional treatments because of the sharp dose gradients between edges of the target volume and OARs. (b) In this
work is observed that the decreased amount of the PTVs between 0 and 60 cm3, is independent of the amount of weight loss of
the patient. Replanning is required from anatomical changes produced of losing weight and is independent of the amount. (c) Is
necessary in treatment planning, the continuing education of staff members who attend.
http://dx.doi.org/10.1016/j.rpor.2013.03.270
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Background. Rarely oral cavity carcinoma is diagnosed in asymptomatic phase of growth grade squamous cell tumors. The purpose
of this study was to determine the relationship between symptoms/signs of the disease leading to the delay between the start
of the same and diagnosis (TDD), as well as between diagnosis and initiation of treatment (TDT).
Methods. We review a database of 381 patients of primary squamous cell carcinoma of head and neck between 1992 and 2011.
We selected 92 patients with tumor localization in oral cavity. We included demographic, clinical and tumor characteristics.
Univariate analysis was performed to examine the association of the main symptoms of the disease with TDD and TDT. A p
value less than or equal to 0.05 was considered statistically signiﬁcant. The analysis was performed using SPSS 12.0.
Results. The median age was 63 years (interquartile range=17). Most belonged to males (92.4%). The main symptoms distribution
was in the following order: pain (30.7%), mass (22.7%), ulceration (20.5%), lymphadenopathy (10.2%), dysphonia (5.7%), dysphagia
(3.4%), neurological symptoms (2.3%), itching (2.3%), foreign body sensation (1.1%) and bleeding (1.1%). The median follow-up
of the cohort was 19.3 months (interquartile range=26.3) TDD median was 69 days (interquartile range=108 days). The only
sign that he was associated, was ulceration: positive, with 196 days, vs. negative, with 108 (F=5.012, p= .028). Moreover, the
median for the TDT was 18 days (interquartile range=25 days) and was associated with signs/symptoms of lymphadenopathy
and mass. There were also signiﬁcant differences in the treatments of surgery alone (if = 7 days vs. not = 23, F=6.675, p= .011) and
radiotherapy alone (if: 48 days vs. not = 20, F=4.123, p= .045).
Conclusions. The TDD was associated with signs/symptoms of ulceration and this may be due to patient factors or health system
factors. The TDT was associated with signs/symptoms of lymphadenopathy and mass, probably by the choice of treatment in
these cases, as also demonstrated its by association with surgery and radiation treatments exclusive.
http://dx.doi.org/10.1016/j.rpor.2013.03.271
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Introduction. IMRT, IGRT and 18FDG PET-CT planning is a multimodal combination that allows improving the accuracy of the
planning and treatment delivery in patients with LALC.
Objectives. To assess clinical and acute toxicity outcomes of LALC patients irradiated at our institution, using 18 FDG PET-CT, IMRT
and IGRT. Methods: Between December 2007 and November 2012, all LALC patients treated with radiotherapy at our institution
were included in this analysis.
Results. A total of 43 LALC patients were analyzed. While the 53.5% of patients (23/43) were irradiated with adjuvant intent, the
remaining 20 patients (46.5%) received radical radiotherapy. According to radiation treatment, IMRT was used in the 83.7%
(37/43) of the patients and 3DRT in 16.3%. CT was used for treatment planning in 19 patients (44.2%) and 18FDG PET-CT
in 24 patients (55.8%). Prescription dose in 81.4% of patients (N: 35) was 66Gy in 30 fractions of 2.2Gy per fraction (Inte-
grated Boost) in the areas of gross disease and 54Gy in 30 fractions of 1.8Gy in areas of microscopic involvement risk.
Treatment veriﬁcation in all cases was Cone Beam-CT (IGRT). A total of 13 patients out of 43 (30.2%) were carriers of gas-
trostomy feeding tube. The mean follow-up was 12 months (median 8 months; range 0.5–58.6 months) with a 1-year local
failure free survival (LFFS) of 94% and an actuarial 2-year LFFS of 90.2%. Acute toxicity G3-G4 was reported in 17.6% of
patients.
